Contact Us (781) 301-7474

Latest Updates

Hemanext to Present New Red Blood Cell Research Data at AABB 2020

Hemanext Inc., a privately held medical technology company dedicated to improving the quality, safety, efficacy and cost of red blood cell (RBC) transfusions, today announced that it will present four new abstracts on the potential benefits of hypoxic storage of RBCs through its online booth during the American Association of Blood Banks (AABB) Virtual Annual Meeting Oct. 3-5, 2020.

read more

Thalassaemia International Federation and Hemanext® Inc. Announce New Strategic Alliance

The Thalassaemia International Federation (TIF), a worldwide organization dedicated to ensuring equal access to quality healthcare for every patient with thalassaemia and other hemoglobin disorders across the world, and Hemanext Inc., a privately held medical technology company dedicated to improving patients’ quality of life by delivering a better red blood cell (RBC) replacement therapy, today announced a new strategic alliance on behalf of people living with thalassaemia.

read more

CONNECT WITH HEMANEXT TODAY TO LEARN MORE!

We are happy to answer any questions about the company, our technology, or our research. Fill out the form below and we will connect with you!

Privacy


We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here.